The U.S. Food and Drug Administration (FDA) granted fast-track designation to RC18, in development by a company in China, RemeGen.
The FDA defines fast track as “a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.”
RC18 is a recombinant protein, made in the lab with parts of naturally produced human proteins that blocks both lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL).
By blocking these molecules, the experimental therapy aims to suppress the development and survival of plasma cells and mature B-cells, which produce the autoantibodies that attack tissues in autoimmune diseases. RC18 has little impact on early and memory B-cells, which are important for immune defense.
For further information on RC18 please click here.
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.